English-arkiv - Sida 3 av 21

Final Push of the Subscription Period for Chordate Medical’s Rights Issue

The subscription period for Chordate Medical’s ongoing rights issue runs until Monday, February 17, 2025. However, some banks may close the subscription earlier.

Subscription can be made with Bank-ID here, or through your bank or broker. In the rights issue, a unit consisting of one ordinary share and one preference share, intended to be listed on Nasdaq First North Growth Market, is being issued. The subscription price for one unit is 12 SEK.

"The primary goal of this capital raise is to continue driving the ongoing exit process to a desired outcome, and in addition, to finance the activities and measures we believe are necessary to achieve that," says Anders Weilandt, CEO of Chordate.

CEO Anders Weilandt is interviewed about the rights issue here (In Swedish)

In the event of full subscription in the rights issue, the Company will receive net cash of approximately SEK 20.6 M (after issue costs). The net proceeds are intended to be used for the following purposes, listed in order of priority:

General company purposes (approx. 50 percent)
Completion of clinical studies (approx. 10 percent)
Continued processing of focus markets (approx. 30 percent)
Investments in production capacity (approx. 10 percent)

Information memorandum and more details about the rights issue (In Swedish)

About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine, a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at www.chordate.com

The company's Certified Adviser on Nasdaq First North Growth Market Stockholm is Vator Securities AB.

N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.

Final Push of the Subscription Period for Chordate Medical’s Rights Issue

Correction: Additional Major Shareholders Announce Full Subscription in Chordate Medical’s Ongoing Rights Issue

The press release published today, February 5, 2025, at 15:35 CET, gave an incorrect impression of the total securing of the ongoing rights issue. Below is a corrected version of the press release, where the last paragraph has been corrected.

Two of Chordate Medical’s ten largest shareholders have informed the company of their intention to subscribe for Units in the ongoing rights issue.

Hawoc Investment AB had previously committed to a subscription of SEK 500,000. In addition to this, Hawoc has now informed the company that they intend to subscribe to their full pro rata right in the ongoing issue, amounting to a total of SEK 2,122,000, including the original commitment. Hawoc Investment AB is the company's second-largest shareholder.

Furthermore, David Nyman has informed the company of his intention to subscribe to his pro rata right, equivalent to SEK 528,000.

"It is highly gratifying to receive this strong support for the company and the rights issue from our major shareholders. The confirmation of continued support and confidence in our strategic plan from so many of our principal owners is of crucial importance to the company," says Anders Weilandt, CEO of Chordate.

This means that a number of existing shareholders in Chordate Medical have now collectively entered into subscription commitments and declarations of intent for a total amount of circa 9.9 MSEK, which corresponds to circa 44.6 percent of the issue.

Correction: Additional Major Shareholders Announce Full Subscription in Chordate Medical’s Ongoing Rights Issue

Additional Major Shareholders Announce Full Subscription in Chordate Medical’s Ongoing Rights Issue

Two of Chordate Medical’s ten largest shareholders have informed the company of their intention to subscribe for Units in the ongoing rights issue.

Furthermore, David Nyman has informed the company of his intention to subscribe to his pro rata right, equivalent to SEK 528,000.

This means that Chordate Medical's rights issue will now be subscribed for an additional circa 9.7 percent, bringing the total subscription level to at least circa 90 percent. In other words, the company will receive an additional circa SEK 2.2 million, or a total of at least circa SEK 20 million.

Additional Major Shareholders Announce Full Subscription in Chordate Medical’s Ongoing Rights Issue

Chordate Medical publishes information memorandum in connection with rights issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, HONG KONG, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, RUSSIA, BELARUS OR IN ANY OTHER JURISDICTION IN WHICH THE PUBLICATION OR DISTRIBUTION OF THIS PRESS RELEASE WOULD BE ILLEGAL, BE SUBJECT TO LEGAL RESTRICTIONS OR WOULD REQUIRE REGISTRATION OR OTHER ACTION.

Chordate Medical Holding AB ("Chordate Medical" or the "Company") has prepared an information memorandum (the "Memorandum") regarding the Company's upcoming issue of units with preferential rights for existing shareholders (the "Rights Issue"), which the board decided on 23 December 2024 and published on the same day.

The record date for obtaining unit rights in the Rights Issue is January 31, 2025.

The subscription period in the Rights Issue runs from and including February 3, 2025 to and including February 17, 2025.

The Memorandum is available on the Company's website, www.chordate.com, together with all other information related to the Rights Issue. The Memorandum will also be available on Bergs Securities' website, www.bergssecurities.se.

Advisers
Chordate has engaged Bergs Securities as financial advisor and issuing agent in connection with the Rights Issue. CMS Wistrand is legal advisor in connection with the Rights Issue.

Important information
Publication, announcement or distribution of this press release may in some jurisdictions be subject to restrictions by law and persons in the jurisdictions where this press release has been published or distributed should inform themselves of and comply with such legal restrictions. The recipient of this press release is responsible for using this press release and the information contained herein in accordance with the applicable regulations of the respective jurisdiction. This press release does not constitute an offer to sell or an invitation regarding an offer to acquire or subscribe for securities issued by the Company in any jurisdiction where such offer or invitation would be unlawful. In a member state of the European Economic Area ("EEA"), securities referred to in this press release may only be offered in accordance with the applicable exemptions in Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (the "Prospectus Regulation").

This press release does not constitute an offer or invitation to acquire or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States without registration, or without application of an exemption from registration, under the then-current U.S. Securities Act of 1933 ("Securities Act"), and may not be offered or sold in the United States without being registered, subject to an exemption from, or in a transaction not subject to the registration requirements of the Securities Act. There is no intention to register any securities mentioned herein in the United States or to make a public offering of such securities in the United States. The information in this press release may not be published, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, in or to the United States, Australia, Japan, Canada, Hong Kong, New Zealand, Switzerland, Singapore, South Africa, Russia, Belarus or any other jurisdiction where such publication, publication or distribution of this information would be in conflict with current regulations or where such an action is subject to legal restrictions or would require additional registration or other measures than what follows from Swedish law. Actions contrary to this instruction may constitute a violation of applicable securities legislation.

This press release is not a prospectus within the meaning of the Prospectus Ordinance and has not been approved by any regulatory authority in any jurisdiction. The company has not approved any offer to the public of securities in any member state of the EEA and no prospectus has been drawn up or will be drawn up in connection with the Rights Issue. In each EEA Member State, this notice is directed only to "eligible investors" in that Member State as defined in the Prospectus Regulation. This press release neither identifies nor purports to identify any risks (direct or indirect) that may be associated with an investment in shares. An investment decision to acquire or subscribe for Units in the Rights Issue may only be made based on publicly available information.

To the extent this press release contains forward-looking statements, such statements do not represent facts and are characterized by words such as "should", "expect", "believe", "estimate", "intend", "intend", "assume" and similar expressions. Such statements express Chordate's intentions, opinions or current expectations or assumptions. Such forward-looking statements are based on current plans, estimates and forecasts that Chordate has made to the best of its ability but which Chordate does not claim will be accurate in the future. Forward-looking statements involve risks and uncertainties that are difficult to predict and cannot generally be influenced by Chordate. It should be kept in mind that actual events or outcomes may differ materially from those contained in, or expressed in, such forward-looking statements.

Chordate Medical publishes information memorandum in connection with rights issue

Bulletin from the Extraordinary General Meeting of Chordate Medical Holding AB (publ)

The following resolutions was adopted at the extraordinary general meeting of Chordate Medical Holding AB (publ) held on 28 January 2025

Amendment of the articles of association
The general meeting resolved to amend the company's articles of association by introducing a new class of shares, preference shares, and introducing a redemption clause for the preference shares, as well as adopting new limits for the share capital and the number of shares.

Reduction of the share capital for allocation to the unrestricted equity
The general meeting resolved on a reduction of the company's share capital by SEK 6,650,856 for allocation to the unrestricted equity. The reduction is carried out without the withdrawal of shares. The share capital will after the reduction amount to SEK 4,433,904.

Approval of the board of directors’ resolution on the new issue of units
The general meeting resolved to approve the board of directors’ resolution on 23 December 2024 to issue not more than 1,847,460 units, observing the shareholders preferential rights. The issue of units is carried out on the following main terms. Each unit consist of one new ordinary share and one new preference share. In total, the issue encompasses not more than 1,847,460 ordinary shares and not more than 1,847,460 preference shares. Upon full subscription of all shares issued in the unit issue, the share capital will increase by not more than SEK 14,779,680.

The subscription price for each unit shall be SEK 12, corresponding to a subscription price of SEK 8 for each ordinary share and SEK 4 for each preference share. Subscription of units with preferential rights shall be made using unit rights. The right to receive unit rights to subscribe for units with preferential rights shall be granted to those who are registered as shareholders on the record date. The record date for receiving unit rights and the right to participate in the issue with preferential rights shall be 31 January 2025. Each existing share entitles to one unit right, and three unit rights entitles to the subscription of five units. Subscription of units with the support of unit rights shall be made during the period from and including 3 February 2025 to and including 17 February 2025. The preference shares are subject to a redemption clause.

Provided that the rights issue is fully subscribed, the company will initially receive approximately SEK 22.2 million before issue costs.

The company has received subscription undertakings from certain existing shareholders as well as members of the board of directors and the executive management, amounting to a total of approximately SEK 7.9 million. The company has also entered into agreements with a number of external investors regarding bottom guarantee commitments of a total of approximately SEK 7.6 million. In addition, the company has entered into agreements with three of the company’s largest shareholders and the chairman of the board, Otto Skolling, regarding top guarantee commitments of a total of approximately SEK 2.3 million. In aggregate, the issue of units is covered by subscription undertakings and guarantee commitments amounting to approximately 79.9 percent.

Authorization for the board of directors to resolve on a new issue
The general meeting resolved to authorize the board of directors to, until the next annual general meeting, on one or more occasions, with deviation from the shareholders' preferential rights and with or without conditions for set-off or other conditions, resolve on the issuance of ordinary shares and preference shares to those who have entered into guarantee commitments in order to ensure the preferential rights issue decided by the board of directors on 23 December 2024 and to those who have subscribed for units in the rights issue in case the rights issue is over subscribed. Upon exercise of the authorisation, the terms and conditions for the units shall be the same as in the rights issue decided by the board of directors on 23 December 2024, meaning that each unit shall consist of one new ordinary share and one new preference share. The number of ordinary shares and preference shares that may be issued under the authorisation may not exceed 829,834 shares (414,917 ordinary shares and 414,917 preference shares), i.e. the sum of 600,000 shares (300,000 ordinary shares and 300,000 preference shares) in the over-allotment issue and 229,834 shares (114,917 ordinary shares and 114,917 preference shares) which is the total number of shares corresponding to the agreed guarantee compensation to be paid by the company to those who have entered into guarantee commitments in order to ensure the preferential rights issue.

Bulletin from the Extraordinary General Meeting of Chordate Medical Holding AB (publ)

Groundbreaking Migraine Study on Ozilia Now Published in Prestigious Neurology Journal

The highly esteemed scientific journal Neurology has published the scientific article on Chordate Medical’s pivotal PM007 registration study on preventive neurostimulation treatment for chronic migraine.

“This publication confirms that the medical efficacy of the Ozilia treatment is on par with conventional drug-based alternatives for the preventive treatment of chronic migraine, a market estimated at approximately USD 8 billion in sales globally, with strong growth,” says Anders Weilandt, CEO of Chordate.

The publication signifies that the article and the study’s results have undergone a peer review by an independent expert panel. The journal’s review has given the study’s methodology and results the highest classification, Class I, as evidence that intranasal kinetic oscillation stimulation is associated with a reduced number of headache days per month in patients with chronic migraine.

In the article, the authors write about Ozilia (formerly K.O.S):

"The Chordate System provides significant benefits to patients with Chronic Migraine by reducing the number of Monthly Headache Days. The nonpharmacologic nature of the treatment option positions K.O.S as a valuable addition to the current therapeutic portfolio for the management of Chronic Migraine.”

The article, titled “Kinetic Oscillation Stimulation for the preventive treatment of chronic migraine – a randomized, double-blind, sham-controlled trial,” reports that the primary efficacy measure in the PM007 study demonstrated a significantly greater reduction in average monthly headache days (MHD) during the measurement period with active treatment (-3.5 days, n=67) compared to sham/placebo treatment (-1.2 days, n=65, p=0.0132). Compared to the sham treatment, active treatment also consistently resulted in a significant reduction in MHD during the follow-up period (-2.7 days [-4.3; -1.0, p=0.0014]). Similarly, the key secondary efficacy measure, average monthly migraine days (MMD), showed a significant reduction during both the measurement period (-2.4 days [-4.1; -0.7, p=0.0048]) and the follow-up period (-2.9 days [-4.5; -1.2, p=0.0008]).

“It is rare for medical technology in a clinical study to demonstrate this level of clarity and significance, and the importance of this publication for the company’s value can hardly be overstated,” says Anders Weilandt.

The PM007 study was registered on clinicaltrials.gov (NCT03400059) on January 17, 2018. The first patient was recruited on March 22, 2018, and the last patient completed the study on October 1, 2022. Five clinics in Germany and four in Finland recruited the study’s 132 patients, all diagnosed with chronic migraine. Half of the patients were randomized to active Ozilia treatment, while the other half received sham/placebo treatment. No treatment-related serious adverse events were observed.

Patients are diagnosed with chronic migraine if they have experienced more than 15 headache days per month, including at least 8 migraine episodes, for a minimum of three months.

The full article is available via open access at: https://www.neurology.org/doi/10.1212/WNL.0000000000210220

Groundbreaking Migraine Study on Ozilia Now Published in Prestigious Neurology Journal

Chordate Expands Follow-Up Study PM010 with Key University Clinic in Switzerland

Chordate is adding a 12th study clinic to the post-market surveillance study for migraine treatment as Inselspital, Universitätsklinik für Neurologie, in Bern (CH) has received ethical approval to join the study. The principal investigator at the clinic is Prof. Dr. Christoph Schankin, a widely respected opinion leader both nationally and internationally.

"The PM010 study is progressing well, with approximately 40 percent of the maximum number of patients currently recruited. One of the study's goals is to obtain as broad an overview as possible of different markets and healthcare models, which is why it is important that our new focus market, Switzerland, is also represented in the study. Inselspital in Bern is also an important reference clinic for Neurolite, our Swiss distributor," says Anders Weilandt, CEO of Chordate.

PM010 is an ongoing open clinical post-market surveillance to monitor long-term outcomes and safety of Ozilia® in patients with chronic migraine under routine clinical care. The study is designed to recruit up to 200 patients and is being conducted at 12 clinics across four European countries, with a follow-up period of 12 months. Data from this study will be reported at intervals and also be used to refine recommendations for the clinical treatment regimen.

Chordate Expands Follow-Up Study PM010 with Key University Clinic in Switzerland

Notice of extraordinary general meeting of Chordate Medical Holding AB (publ)

Shareholders in Chordate Medical Holding AB (publ), reg. no. 556962-6319, are hereby convened to the extraordinary general meeting to be held on Tuesday, 28 January 2025 at 17:00 at the company’s office, Regus, Kistagången 20 B in Kista. Admission and registration will take place from 16:30.

Registration and notification
Shareholders who wish to attend the general meeting shall

be entered in the share register maintained by Euroclear Sweden AB as of Monday, 20 January 2025, and
give notice of their intention to attend the meeting no later than Wednesday, 22 January 2025 by mail to Chordate Medical Holding AB (publ), c/o Regus, Kistagången 20 B, 164 40 Kista (please mark the envelope ”EGM Chordate”), by telephone +46 8 400 115 46 or by e-mail to niklas.lindecrantz@chordate.com.

Shareholders whose shares are registered in the name of a nominee through a bank or other nominee are entitled to participate in the meeting as follows. In addition to registering for the meeting, such shareholders must re-register their shares in their own name so that the shareholder is registered in the share register maintained by Euroclear Sweden AB on the record date of 20 January 2025. Such re-registration may be temporary (so-called voting right registration). Shareholders who wish to register their shares in their own name must, in accordance with the respective nominee's procedures, request that the nominee makes such registration. Voting right registrations requested by shareholders in such time that the registration has been made by the nominee no later than 22 January 2025 will be taken into account in the preparation of the share register.

Proxies
If a shareholder wishes to attend the general meeting by proxy, a written and dated power of attorney signed by the shareholder in original shall be sent by post to Chordate Medical Holding AB (publ), c/o Regus, Kistagången 20 B, 164 40 Kista. A proxy form is available on the company's website www.chordate.com. If the shareholder is a legal entity, a certificate of registration or other authorisation document must be attached to the form.

Matters at the general meeting

Opening of the general meeting
Election of chairperson of the meeting
Preparation and approval of the voting register
Election of one or two persons who shall approve the minutes
Determination of whether the general meeting has been duly convened
Approval of the agenda
Resolution on amendments to the articles of association (step 1)
Resolution on
1. amendments to the articles of association (step 2)
2. reduction of the share capital for allocation to unrestricted equity
3. amendments to the articles of association (step 3)
4. approval of the board's resolution to issue new units consisting of Ordinary Shares and Preference Shares with preferential rights for existing shareholders
Resolution on authorization to the board to issue Ordinary Shares and Preference Shares.
Resolution on authorization to the board to make minor adjustments to the resolutions
Close of meeting

Proposals for resolution
The proposals below in items 7-9 are conditional upon approval of each other, which is why the proposals shall be resolved on in a joint resolution. A valid resolution in accordance with items 7-9 requires the support of shareholders representing at least two-thirds of both the votes cast and the shares represented at the meeting.

Item 7 – Resolution on amendments to the articles of association (step 1)
The board proposes that the general meeting resolves to amend the company's articles of association by introducing a new class of shares, Preference Shares, and by introducing a redemption clause for Preference Shares, essentially as follows.

Current wording	Proposed wording
§ 4 Share capital and number of shares	§ 4 Share capital
The share capital shall be not less than SEK 9,000,000 and not more than SEK 36,000,000.The number of shares shall be not less than 900,000 and not more than 3,600,000.	The share capital shall be not less than SEK 9,000,000 and not more than SEK 36,000,000.
	§ 5 Shares
	Number and class of shares The number of shares shall be not less than 900,000 and not more than 3,600,000.Shares may be issued in two classes, designated as Ordinary Shares and Preference Shares. Each Ordinary Share shall carry one vote. Each Preference Share shall carry one tenth vote. All classes of shares may be issued up to an amount corresponding to a maximum of 100 per cent of the share capital.Dividends on Preference Shares Preferential dividend event In the event of (i) the company's divestment of more than half of the shares in the wholly owned subsidiary Chordate Medical AB, reg. no. 556682-5062 (the ”Operating Company”), (ii) the Company's or the Operating Company's divestment of essentially the whole business and assets of the Operating Company, (iii) a bona fide offer for the Company (including the Operating Company) that is brought to the Company's attention or (iv) liquidation of the Operating Company, dissolution of the Operating Company or bankruptcy of the Operating Company (each such event a ”Preferential Dividend Event”), an amount equal to the assets of the Company, and/or the funds, and/or the purchase price including the earn-out (net of transaction costs) attributable to such Preferential Dividend Event (the ”Holding”) shall be distributed to the shareholders as follows:The Preference Shares shall, in the event of a Preferential Dividend Event, receive a value from the Holding equal to the Preferential Amount (as defined below) in priority to the Ordinary Shares. If the Holding is not sufficient to pay the full Preferential Amount per Preference Share, each Preference Share shall be entitled to its pro rata portion of the Holding.Preferential Amount The Preference Shares entitle to a maximum dividend amount of SEK 12 (the ”Preferential Amount”) per Preference Share.Recalculation in case of certain corporate events In the event of a change in the number of Preference Shares as a result of a reverse share split, split or other similar corporate event, the amount to which the Preference Share entitles shall be recalculated to reflect such change.Dissolution of the company If the company is dissolved, Preference Shares shall carry a preferential right over Ordinary Shares to receive from the company's assets an amount per Preference Share equal to what would have been received if the shares had been redeemed in accordance with the provision below, prior to distribution to holders of Ordinary Shares.Other The Preference Shares shall not otherwise confer any right to dividends or to a share in the profits. No dividend on the Ordinary Shares shall be paid until the Preferential Amount has been paid in full to the holders of the Preference Shares, whether or not a Preferential Distribution Event has occurred.Redemption of Preference Shares The share capital may be reduced, through a redemption of Preference Shares, although not below the minimum share capital, by the board of directors adopting a resolution in accordance with the following principles.The board of directors’ decision to redeem Preference Shares may only relate to all, and not only part, of the outstanding Preference Shares.The holder of a Preference Share which is subject to redemption shall be obliged, within three months of the date on which he was informed of the resolution regarding redemption to receive redemption of the share in an amount calculated as follows: the Preferential Amount less any dividends paid out of the Holding, but not less than the quota value of the share.The board of directors may, in the event of a Preferential Dividend Event, decide to redeem Preference Shares instead of making a dividend distribution out of the Holding. The redemption amount shall then be equal to the Preferential Amount.Shareholders' preferential rights Where the company resolves to issue new Ordinary Shares and Preference Shares by way of a cash issue or a set-off issue, holders of Ordinary Shares and Preference Shares shall have pre-emptive rights to subscribe for new shares of the same class in proportion to the number of shares previously held by the holder (primary pre-emptive rights). Shares not subscribed for with primary pre-emptive rights shall be offered to all shareholders for subscription (subsidiary pre-emptive rights). If the shares thus offered are not sufficient for the subscription made with subsidiary pre-emptive rights, the shares shall be distributed among the subscribers in proportion to the total number of shares they already own in the company, regardless of whether these are Ordinary Shares or Preference Shares, and, to the extent that this cannot be done, by drawing lots.If the company decides to issue only Ordinary Shares or Preference Shares by way of a cash issue or set-off issue, all shareholders, irrespective of whether their shares are Ordinary Shares or Preference Shares, shall have preferential rights to subscribe for new shares in proportion to the number of shares of held.Where the company resolves to issue warrants or convertibles by way of a cash issue or set-off issue, the shareholders have pre-emptive rights to subscribe for warrants as if the issue concerned the shares that may be newly subscribed for by virtue of the warrant and pre-emptive rights to subscribe for convertibles as if the issue concerned the shares for which the convertibles may be exchanged.The provisions above shall not entail any restrictions on the possibility for the company to adopt a resolution regarding a cash issue or set-off issue without regard to shareholders’ pre-emption rights.Upon an increase in the share capital by way of a bonus issue, new shares of each class shall be issued in proportion to the number of shares of the same class already in issue. In that event, old shares of a given class shall carry the right to new shares of the same class. The aforementioned shall not entail any restrictions on the possibility for the company to issue shares of a new class through a bonus issue, following any necessary amendments to the articles of association.

Existing shares shall constitute Ordinary Shares.

Item 8 a – Resolution on amendments to the articles of association (step 2)
The board proposes that the general meeting resolve to amend the company's articles of association by adopting new limits on the share capital and the number of shares as follows.

Proposed wording

§ 4 Share capital

The share capital shall be not less than SEK 4,400,000 and not more than SEK 17,600,000.

Item 8 b) – Reduction of the share capital for allocation to unrestricted equity

The board of directors proposes that the general meeting resolves on a reduction of the share capital on the following terms and conditions.

The purpose of the share capital reduction is allocation to unrestricted equity.
The company’s share capital shall be reduced by SEK 6,650,856.
The reduction of the share capital shall be carried out without withdrawal of shares.

Following the reduction, the company's share capital will amount to SEK 4,433,904, which implies a quota value of SEK 4.

Item 8 c – Resolution on amendments to the articles of association (step 3)
The board proposes that the general meeting resolve to amend the company's articles of association by adopting new limits on the share capital and the number of shares as follows.

Proposed wording

§ 4 Share capital

The share capital shall be not less than SEK 6,000,000 and not more than SEK 24,000,000.

§ 5 Shares

The number of shares shall be not less than 2,000,000 and not more than 8,000,000.

Item 8 d – Resolution on approval of the board's resolution to issue new units consisting of Ordinary Shares and Preference Shares with preferential rights for existing shareholders
The board proposes that the general meeting resolves to approve the board's decision of 23 December 2024 to issue a maximum of 1,847,460 units consisting of Ordinary Shares and Preference Shares on the following main terms.

1. Each unit consists of one (1) new ordinary shares and one (1) new preference shares. In total, the issue comprises a maximum of 3,694,920 shares, corresponding to a maximum increase in share capital of SEK 14,799,680.

2. The subscription price for each unit shall be SEK 12, corresponding to a subscription price of SEK 8 per Ordinary Share and SEK 4 per Preference Share.

3. Subscription of units with pre-emptive rights is based on unit rights. The right to receive unit rights to subscribe for units with preferential rights shall be granted to those who are registered as shareholders on the record date and are thereby allocated unit rights in relation to their shareholding on the record date.

4. The record date for receiving unit rights and the right to participate in the rights issue with pre-emptive rights shall be 31 January 2025.

5. Each existing share entitles the holder to one (1) unit right and three (3) unit rights entitle the holder to subscribe for five (5) units.

6. If not all units are subscribed for on the basis of unit rights, the remaining units shall be allocated within the framework of the maximum amount of the issue:

primarily to those who have subscribed for units with unit rights (regardless of whether they were shareholders on the record date or not) and who have expressed an interest in subscribing for units without unit rights and, in the event that allotment to them cannot be made in full, allotment shall be made pro rata in relation to the number of unit rights that each of those who have expressed an interest in subscribing for units without unit rights have utilised for subscription of units;
secondarily to others who have subscribed for units in the issue without the support of unit rights and, in the event that allocation to these cannot be made in full, allocation shall be made pro rata in relation to the total number of units for which the subscriber has applied for subscription; and
thirdly, to those who have provided guarantee commitments regarding subscription of units, in proportion to such guarantee commitments.

To the extent that allocation at any stage as described above cannot be made on a pro rata basis, allocation shall be made by drawing of lots.

7. Subscription of units with unit rights shall be made by cash settlement during the period from and including 3 February 2025 up to and including 17 February 2025. Subscription of units without unit rights shall be made on a separate subscription list during the same time as subscription with unit rights shall be made. Payment for units subscribed for without unit rights shall be made no later than the third banking day after notification of allotment has been sent to the subscriber through a contract note.

8. The board shall be authorised to extend the subscription and payment period.

9. Subscription may only be made of units and thus not of Ordinary Shares or Preference Shares individually. Allotment may only be made of units. However, after completion of the issue, the Ordinary Shares and Preference Shares will be separated.

10. The shares issued through the unit issue entitle to dividends as of the first record date for dividends that occurs immediately after the new shares are entered in the share register maintained by Euroclear Sweden AB.

11. The Preference Shares are subject to a redemption clause.

12. The share premium shall be transferred to the unrestricted premium reserve.

13. The rights issue requires an amendment to the limits of the share capital and the number of shares in the company's articles of association in accordance with resolution item 8 c.

Item 9 – Resolution on authorization to the board to issue Ordinary Shares and Preference Shares.
In order to enable the issue of units consisting of Ordinary Shares and Preference Shares as guarantee compensation to the guarantors (the “Guarantors”) to secure the rights issue of units resolved upon by the board on 23 December 2024, and proposed to be approved under item 8 d on the agenda, and in order to enable an over-allotment issue in case the rights issue is over subscribed, the board proposes that the general meeting resolves to authorise the board, for the period until the next annual general meeting, on one or more occasions, with deviation from the shareholders' preferential rights and with or without conditions regarding set-off or other conditions, to resolve on the issue of Ordinary Shares and Preference Shares to the Guarantors and to those who have subscribed for units in the rights issue in case the rights issue is over subscribed.

Upon exercise of the authorisation, the terms and conditions for the units shall be the same as in the rights issue, meaning that each unit shall consist of one (1) new Ordinary Shares and one (1) new Preference Shares.

The purpose of the authorisation and the rationale for the deviation from the shareholders' preferential rights is to be able to issue units as guarantee compensation to the Guarantors and in order to enable an over-allotment issue to those who have subscribed for units in the rights issue in case the rights issue is over subscribed. The number of Ordinary Shares and Preference Shares that may be issued under the authorisation may not exceed 829,834 shares (414,917 Ordinary Shares and 414,917 Preference Shares), i.e. the sum of 600,000 shares (300,000 Ordinary Shares and 300,000 Preference Shares) in the over-allotment issue and 229,834 shares (114,917 Ordinary Shares and 114,917 Preference Shares) which is the total number of shares corresponding to the agreed guarantee compensation to be paid by the company to the Guarantors.

Item 10 – Resolution on authorization to the board to make minor adjustments to the resolutions
It is proposed that the board, or the person appointed by the board, be authorised to make such minor adjustments to the resolutions adopted by the general meeting under items 7 – 9 as may prove necessary in connection with the registration of the resolutions with the Swedish Companies Registration Office or Euroclear Sweden AB.

The board of directors’ statement in accordance with Chapter 20 Section 13 fourth paragraph of the Swedish Companies Act

In order to achieve a lower quota value, the board of directors has proposed that the company’s share capital, which currently amounts to SEK 11,087,760 divided into 1,108,476 shares, each with a quota value of SEK 10, shall be decreased without the withdrawal of shares and for allocation to the unrestricted equity.
The effect of the board of directors’ proposal under item 8 b is that the company’s share capital is reduced by SEK 6,650,856, from SEK 11,087,760 to SEK 4,433,904, whereby the quota value amounts to SEK 4. The board of directors has in connection with this resolved to propose that the extraordinary general meeting resolves on a rights issue (item 8 d), approximately 79.9 per cent of which is covered by subscription and guarantee commitments, through which the company’s share capital is increased by at least SEK 6,650,856. By carrying out the rights issue that increases the share capital with the reduction amount simultaneously with the reduction, the company may execute the reduction resolution without authorization from the Swedish Companies Registration Office or general court, since the measures jointly means that neither the company’s restricted equity nor its share capital is decreased.

Other
The board and the managing director shall, if any shareholder so requests and the board considers that it can be done without material harm to the company, provide information on circumstances that may affect the assessment of an item on the agenda.

Complete proposals for resolutions in accordance with the above and documents in accordance with the Swedish Companies Act (2005:551) will be available at the company and on the company's website, www.chordate.com, no later than two weeks prior to the general meeting. Copies of these documents will be sent free of charge to shareholders who so request and state their address.

For the processing of personal data, please refer to the privacy policy available at the following link: https://www.euroclear.com/dam/ESw/Legal/Integritetspolicy-bolagsstammor-svenska.pdf

___________________________

Stockholm in December 2024

Chordate Medical Holding AB (publ)

The board of directors

Notice of extraordinary general meeting of Chordate Medical Holding AB (publ)

Chordate decides on a preferential issue of units of approximately SEK 22.2 million consisting of ordinary shares and preference shares with a conditional share dividend upon sale of the business

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, RUSSIA, BELARUS, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, OR IN ANY OTHER JURISDICTION IN WHICH THE PUBLICATION OR DISTRIBUTION OF THIS PRESS RELEASE WOULD BE ILLEGAL, BE SUBJECT TO LEGAL RESTRICTIONS OR WOULD REQUIRE REGISTRATION OR OTHER ACTION.

The board of Chordate Medical Holding AB (publ) ("Chordate" or the "Company") has today decided to carry out an issue of units consisting of Ordinary Shares and Preference Shares for an initial amount of approximately SEK 22.2 million (the "Rights Issue") with preferential rights for the Company's existing shareholders subject to the approval of the extraordinary general meeting. Notice of the extraordinary general meeting will be published shortly. The subscription price for a unit, consisting of an Ordinary share and a Preference share, amounts to SEK 12 ("Unit"). Around 79.9 percent of the Rights Issue is covered by subscription undertakings and guarantee commitments.

Summary

The board of Chordate has today decided on the Rights Issue subject to approval from an extraordinary general meeting. Notice to the extraordinary general meeting will be published shortly.
In order to enable the Rights Issue, the board has also decided to propose to the extraordinary general meeting to make a decision to i) introduce a new class of shares, Preference Shares, ii) introduce a redemption clause regarding the Preference Shares in the Company's articles of association, and iii) change the share and share capital limits in the Company's articles of association.
The net proceeds from the Rights Issue are intended to be used for the following purposes listed in order of priority; general corporate purposes, completion of clinical trials, continued efforts in focus markets and investments in production capacity.
The rights issue will, if fully subscribed, raise approximately SEK 22.2 million before issue costs. The issue costs for the Rights Issue are estimated to amount to approximately SEK 3.0 million including compensation for guarantees of approximately SEK 1.4 million, which is paid through newly issued Units, which means that the Company is expected to receive net cash of approximately SEK 20.6 million.
Anyone who is a shareholder in Chordate on the record date of January 31, 2025 has preferential rights to subscribe for Units in the Rights Issue in relation to the number of shares held on the record date.
One (1) existing share in Chordate on the record date entitles to one (1) unit right, three (3) unit rights gives the right to subscribe for five (5) Units consisting of one (1) Ordinary share and one (1) Preference share.
The subscription price has been set at SEK 12 per Unit.
For existing shareholders who do not participate in the Rights Issue will be diluted with a maximum of 77 percent, including the Preference Shares. Shareholders who do not wish to participate in the Rights Issue have the opportunity to receive financial compensation for the dilution by selling their unit rights.
The subscription period in the Rights Issue is estimated to run from and including February 3, 2025 to and including February 17, 2025.
The Rights Issue is covered by the subscription undertakings amounting to approximately 35.5 percent of the Rights Issue. No compensation is paid for submitted subscription undertakings.
The company has entered into underwriting guarantees totalling approximately SEK 9.9 million, corresponding to approximately 44.4 percent of the rights issue.
In total, approximately SEK 17.7 million, corresponding to around 79.9 percent, of the Rights Issue is covered by subscription undertakings and guarantee commitments.
The Board has also decided on an over-allotment issue of up to 300,000 Units, which can provide the Company with an additional SEK 3.6 M, conditional on the Rights Issue being oversubscribed.
The board also proposes that the general meeting decide to authorize the board to make a decision on further issue of Units with a deviation from the shareholders' pre-emptive right in order to be able to issue Units as guarantee compensation to the guarantors.

Full terms and instructions for the Rights Issue will be available in the information memorandum, which is expected to be published around January 31, 2025.

The Rights Issue
The Rights Issue containing Units, will, if fully subscribed, raise approximately SEK 22.2 million to Chordate before issue costs.

The Company's shareholders have preferential rights to subscribe for Units in the Rights Issue in relation to the number of shares held on the record date, which is expected to be January 31, 2025. One (1) existing share in the Company on the record date entitles to one (1) unit right, three (3) unit rights gives the right to subscribe for five (5) Units consisting of one (1) Ordinary share and one (1) Preference share.

The subscription price has been set at SEK 12 per Unit. Both Ordinary and Preference Shares are intended to be admitted to trading on the Nasdaq First North Growth Market.

In connection with the implementation of the Rights Issue, a new class of shares, Preference Shares, will be introduced. The preference share is subject to a redemption clause and, under certain specified circumstances, carries the right to a dividend of a maximum of SEK 12 per preference share, with priority over the ordinary shares. Complete terms and conditions for the Preference Shares can be found in the notice published shortly after this press release. In the event of a fully subscribed Rights Issue, a maximum of 1,847,460 Preference Shares and 1,847,460 Ordinary Shares will be issued.

The Board has also decided on an over-allotment issue of up to 300,000 Units which can raise an additional SEK 3.6 million ("Over-allotment Issue"), conditional on the Rights Issue being oversubscribed. The main purpose of the Over-allotment Issue is to strengthen the Company's financial position and to finance the operations during 2025, including the recently initiated sale process of the Company's business.

The authorization and the Guarantee issue
A number of the Company's major shareholders including Sifonen AB, Hawoc Investment AB, Tommy Hedberg, Magnus Brandberg and related parties and the Company's CEO and other management personnel have committed to subscribe for Units for approximately SEK 7.9 million, corresponding to approximately 35.5 percent of the Rights Issue.

In addition, the Company has entered into bottom guarantee commitments with a number of external investors for a total of SEK 7.6 million, corresponding to 34.3 percent of the Rights Issue. Furthermore, three of the company's major shareholders and the chairman of the board, Otto Skolling, have provided top guarantee commitments totalling SEK 2.3 million, corresponding to 10.1 percent of the rights issue. In total, approximately 79.9 percent of the rights issue is covered by subscription undertakings and guarantee commitments.

The board also proposes that the general meeting decide to authorize the board to make a decision on further issue of Units with a deviation from the shareholders' pre-emptive right ("Authorization"). The purpose of the Authorization and the reason for the deviation from the shareholders' preferential right is to be able to carry out the issue of Units as guarantee compensation to the guarantors (the "Guarantee Issue"). The decision on the Authorization presupposes and is conditional on the general meeting deciding to approve the Rights Issue. When exercising the Authorization, the conditions for Units must be the same as in the Rights Issue, meaning that each Unit must consist of 1 new Ordinary Share and 1 new Preference Share. The number of Units that can be issued with the support of the Authorization may not exceed a total of 114,917, which is the total number of Units that corresponds to the agreed guarantee compensation that the Company has to issue to the guarantors.

The proceeds from the Rights Issue will strengthen the Company's financial position and finance operations during 2025, including the sale process of the Company's wholly owned subsidiary Chordate Medical AB, org. no. 556682-5062, (alternatively the business conducted therein) as described below (the "Divestiture").

The subscription period in the Rights Issue is expected to run from and including February 3, 2025 to and including February 17, 2025.

The company intends to publish an information memorandum regarding the Rights Issue around January 31, 2025.

Background and reason
Chordate develops and commercializes Ozilia, a medical device for the treatment of chronic migraine and rhinitis. In a pivotal randomized and placebo-controlled clinical trial, the Company has demonstrated that treatment with Ozilia has a preventive effect on chronic migraine with a significantly reduced number of headache days and days with migraine episodes as a result. Based on the study results, Chordate has received regulatory approval in Europe (CE mark) and commercialization has begun where the system is used for treatment in clinics in Europe and Saudi Arabia.

Migraine is a serious and commonly occurring medical condition, with around two percent of the population suffering from chronic migraine. The migraine treatment market is worth around USD 10 billion, with CGRP-inhibiting antibodies and Botox treatment accounting for just over a third each.

In clinical trials, Ozilia has demonstrated results that are in line with or better than what today's treatment options can achieve. Ozilia is a drug-free alternative that in trials has shown few unexpected side effects and is thus a welcome addition to preventive treatments for a chronic migraine. Ozilia is currently available for treatment at a limited number of clinics.

Chordate assesses that there is significant potential in Ozilia, but that a full-scale commercialization of the product is best done by a larger international company with sufficient resources. Hence, Chordate has initiated a process with the objective of carrying out the divestment to an industrial buyer. In October 2024, the Company announced that a Swiss advisor, Partner International, had been retained to carry out a divestment through a structured sales process.

Chordate bedriver utveckling och kommersialisering av Ozilia, en medicinteknisk produkt för behandling av kronisk migrän och rinit. I en avgörande randomiserad och placebokontrollerad klinisk studie har Bolaget påvisat att behandling med Ozilia har en preventiv effekt på kronisk migrän med signifikant minskat antal huvudvärksdagar och dagar med migränepisoder som resultat. Chordate har, baserat på studieresultaten, erhållit regulatoriskt godkännande i Europa (CE-märke) och kommersialiseringen har inletts där systemet används för behandling vid kliniker i Europa och Saudiarabien.

Migrän är ett allvarligt och vanligt förekommande sjukdomstillstånd där omkring två procent av befolkningen lider av kronisk migrän. Marknaden för behandling av migrän uppgår till omkring 10 miljarder USD där CGRP-hämmande antikroppar samt behandling med Botox står för drygt en tredjedel vardera.

I kliniska studier har Ozilia uppvisat resultat som är i linje med eller bättre än vad dagens behandlingsalternativ kan uppnå. Ozilia är ett läkemedelsfritt alternativ som i studier uppvisat få oväntade biverkningar och utgör därmed ett välkommet tillägg preventiva behandlingar en kronisk migrän. Ozilia finns idag tillgängligt för behandling på ett begränsat antal kliniker.

Chordate bedömer att det finns en betydande potential i Ozilia men att en fullskalig kommersialisering av produkten bäst sker av ett större internationellt bolag med tillräckliga resurser. Därav har Chordate initierat en process med målsättning att genomföra Avyttringen till en industriell köpare. I oktober 2024 offentliggjorde Bolaget att den schweiziska rådgivaren Partner International anlitats för att genom en strukturerad försäljningsprocess genomföra avyttringen.

Use of proceeds
In the event of full subscription in the Rights Issue, the Company will receive net cash of approximately SEK 20.6 M (after issue costs). The net proceeds are intended to be used for the following purposes, listed in order of priority:

General company purposes (approx. 50 percent)
Completion of clinical studies (approx. 10 percent)
Continued processing of focus markets (approx. 30 percent)
Investments in production capacity (approx. 10 percent)

Subscription undertakings and guarantee commitments
A number of the Company's major shareholders including Sifonen AB, Hawoc Investment AB, Tommy Hedberg, Magnus Brandberg and related parties and the Company's CEO and other management personnel have undertaken to subscribe for Units for approximately SEK 7.9 million, corresponding to approximately 35.5 percent of the Rights Issue. No compensation is paid for submitted subscription undertakings.

In addition, the Company has entered into bottom guarantee commitments with a number of external investors for a total of SEK 7.6 million, corresponding to approximately 34.3 percent of the Rights Issue. Furthermore, three of the company's major owners and the chairman of the board, Otto Skolling, have provided top guarantee commitments totalling SEK 2.3 million, corresponding to 10.1 percent of the rights issue. For the guarantee commitments, a compensation of 14 percent is paid out in newly issued Units with the support of the Authorization.

In summary, approximately 79.9 percent of the rights issue is covered by subscription undertakings and guarantee commitments.

Neither subscription undertakings nor guarantee commitments are secured by bank guarantee, pledged assets or the like. Additional information about subscription undertakings and guarantee commitments will be available in the information memorandum that will be published in connection with the Rights Issue.

The record date for participation in the Rights Issue is estimated to be January 31, 2025, and the subscription period for the Rights Issue is expected to run between February 3 and 17, 2025. The last day for trading in Chordate's shares, including the right to participate in the Rights Issue, is estimated to be January 29, 2025.

Subscription can also take place without unit rights. In the event that all Units are not subscribed with the support of unit rights, the board shall, within the limit of the Rights Issue's maximum amount, decide on the allocation of Units that are subscribed without the support of unit rights. In the event of oversubscription, allocation shall be made in accordance with the following principles: First, such allocation shall be made to those who subscribed for Units with the support of unit rights, regardless of whether they were shareholders on the record date or not and who have registered an interest in subscribing to Units without the support of unit rights and for that if allocation to these cannot take place in full, allocation must take place proportionally in relation to the number of unit rights that each of those who have registered an interest in subscribing to Units without the support of unit rights used for subscription of Units. Secondly, such allocation must be made to others who have subscribed for Units in the issue without the support of unit rights, and in the event that allocation to these cannot take place in full, allocation must be made pro rata in relation to the total number of Units for which the subscriber has registered for subscription. Thirdly, allocation must be made to those who have entered into so-called guarantee commitments in proportion to such commitment. To the extent that allocation according to above cannot take place proportionally, allocation shall be by lottery.

Trading in paid subscribed Units (“BTU”) on Nasdaq First North Stockholm is expected to take place during the period from and including February 3, 2025 until the Rights Issue has been registered, which is expected to take place around February 25, 2025.

Information memorandum
Complete terms and information regarding the Rights Issue, as well as information on subscription obligations and guarantee commitments as well as other information about the Company will be provided in an information memorandum which is expected to be published by the Company before the subscription period begins.

Shares and dilution
Due to the issuance decision, in order to enable the size and subscription price of the Rights Issue, the board has also decided to propose to the extraordinary general meeting to decide on changing the share and share capital limits in the Company's articles of association and to decide on reducing the Company's share capital. With the reduction, the quota value for the Company's shares will drop to SEK 4.0. The changes regarding the Company's share capital below are based on the new proposed quota value of SEK 4.0 per share.

Through the Rights Issue, the share capital will increase by up to SEK 14,779,680, from SEK 4,433,904 to SEK 19,213,584. The number of shares will increase by up to 3,694,920 shares, of which 1,847,460 are preference shares, from 1,108,476 shares to 4,803,396 shares. For existing shareholders who do not participate in the Rights Issue, this means a dilution of a maximum of 76.9 percent, including the preference shares, with the possibility of being financially compensated for the dilution effect by selling their unit rights.

If the Over-allotment Issue is fully utilized, the Company's share capital will increase by a further SEK 2,400,000 to a total of SEK 21,613,584 and the number of shares will increase by a further 600,000 new shares, of which 300,000 are preference shares to a total of 5,403,396 shares. For existing shareholders who do not participate in the Rights issue, and if the over-allotment issue is fully utilized, this means a dilution of a maximum of 11.1 percent including preference shares.

In order to restore the share capital, which is a prerequisite to avoid the time delay associated with the requirement for permission to reduce the share capital, the company's board has proposed to the extraordinary general meeting to decide on a bonus issue whereby free funds are returned to the share capital. With the bonus issue, the quota value of the shares will increase again.

Indicative time plan
29 January 2025 – Last day for trading including the right to subscribe for Units supported by unit rights

30 January 2025 – First day of trading excluding the right to subscribe for Units supported by unit rights

31 January 2025 – Record date for participation in the Rights Issue

31 January 2025 – Publication of information memorandum

3 – 17 February 2025 – Subscription period

3 – 13 February 2025 – Trading in unit rights

3 – 25 February 2025 – Trade in BTU

18 February 2025 – Publication of the outcome of the Rights Issue

Advisers
Chordate has engaged Bergs Securities as financial advisor and issuing agent in connection with the Rights Issue. CMS Wistrand is legal advisor in connection with the Rights Issue.

Importan information
Publication, announcement or distribution of this press release may in some jurisdictions be subject to restrictions by law and persons in the jurisdictions where this press release has been published or distributed should inform themselves of and comply with such legal restrictions. The recipient of this press release is responsible for using this press release and the information contained herein in accordance with the applicable regulations of the respective jurisdiction. This press release does not constitute an offer to sell or an invitation regarding an offer to acquire or subscribe for securities issued by the Company in any jurisdiction where such offer or invitation would be unlawful. In a member state of the European Economic Area ("EEA"), securities referred to in this press release may only be offered in accordance with the applicable exemptions in Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (the "Prospectus Regulation").

This press release does not constitute an offer or invitation to acquire or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States without registration, or without application of an exemption from registration, under the then-current U.S. Securities Act of 1933 ("Securities Act"), and may not be offered or sold in the United States without being registered, subject to an exemption from, or in a transaction not subject to the registration requirements of the Securities Act. There is no intention to register any securities mentioned herein in the United States or to make a public offering of such securities in the United States. The information in this press release may not be published, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, in or to the United States, Australia, Japan, Canada, Hong Kong, New Zealand, Switzerland, Singapore, South Africa or any other jurisdiction where such publication, publication or distribution of this information would be in conflict with current regulations or where such an action is subject to legal restrictions or would require additional registration or other measures than what follows from Swedish law. Actions contrary to this instruction may constitute a violation of applicable securities legislation.

Chordate decides on a preferential issue of units of approximately SEK 22.2 million consisting of ordinary shares and preference shares with a conditional share dividend upon sale of the business

Chordate Highlights the Role of 79 Granted Patents in Driving a Successful Exit Process

Chordate has, as previously communicated, initiated an exit process to identify a buyer for its operations. Key factors for a successful exit are the combination of scientific evidence and market results, together with an adequate patent portfolio.

“The revenue potential a buyer sees in the Ozilia treatment technology will determine the price they are willing to pay, likely in competition with others aiming to add Ozilia to an existing product portfolio,” says Anders Weilandt, CEO of Chordate Medical.

Chordate Medical holds 79 granted patents across 9 patent families, spanning 32 countries. These patents provide intellectual property protection for the inventions underlying the company’s products for treating chronic migraine and rhinitis. Each family includes one or more patents, registered in the EU and several other key markets, collectively describing various unique aspects and potential variants of the company’s technology and clinical efficacy. Currently, one patent application is in the review phase and has yet to be granted.

“It’s reasonable to assume that a potential buyer of the business will want to establish a global product sales strategy under patent protection for quite some time. The patents are a fundamental factor in the company’s sales value when a buyer calculates how long they can invest in sales growth with minimal disruption from direct competition,” says Anders Weilandt.

Chordate’s exit strategy focuses on demonstrating market penetration in selected markets. The company’s value is built on three pillars: robust scientific evidence from clinical studies, demonstrating sales success in a number of selected markets, and a comprehensive portfolio of intangible assets, such as patents and trademarks. Since October 2024, Chordate has engaged Partner International Switzerland GmbH as an advisor to find an international buyer for its operations.

Chordate Highlights the Role of 79 Granted Patents in Driving a Successful Exit Process

Final Push of the Subscription Period for Chordate Medical’s Rights Issue

Correction: Additional Major Shareholders Announce Full Subscription in Chordate Medical’s Ongoing Rights Issue

Additional Major Shareholders Announce Full Subscription in Chordate Medical’s Ongoing Rights Issue

Chordate Medical publishes information memorandum in connection with rights issue

Bulletin from the Extraordinary General Meeting of Chordate Medical Holding AB (publ)

Groundbreaking Migraine Study on Ozilia Now Published in Prestigious Neurology Journal

Chordate Expands Follow-Up Study PM010 with Key University Clinic in Switzerland

Notice of extraordinary general meeting of Chordate Medical Holding AB (publ)

Chordate decides on a preferential issue of units of approximately SEK 22.2 million consisting of ordinary shares and preference shares with a conditional share dividend upon sale of the business

Chordate Highlights the Role of 79 Granted Patents in Driving a Successful Exit Process

Pressmeddelanden

Chordate Medical Holding AB (publ) Delårsrapport januari-juni 2025

Chordate meddelar kostnadsreduktion och fokusering på bolagsförsäljning

Chordate redovisar preliminära slutsatser från långtidsstudien om kronisk migrän: PM010

Chordate Medical AB